Daratumumab improves bone turnover in relapsed/refractory multiple myeloma; phase 2 study “REBUILD”

Although not statistically significant, results from the prospective, open-label, phase 2 REBUILD study of patients with relapsed/refractory multiple myeloma receiving daratumumab demonstrated a 3.9% median percent change in C-terminal cross-linking telopeptide of type 1 collagen (CTX) from baseline to 4 months. Further, a 2.6% median percent decrease in tartrate resistant acid phosphatase 5b (TRACP-5b) levels from baseline to 4 months was also seen.